Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma.

[1]  L. Castellano,et al.  Polymeric Carriers for Delivery of RNA Cancer Therapeutics , 2022, Non-coding RNA.

[2]  Chenbo Yang,et al.  Long Non-Coding RNA in Esophageal Cancer: A Review of Research Progress , 2022, Pathology & Oncology Research.

[3]  Marwa Hassan,et al.  Effect of CD133 Polymorphisms on the Risk of Developing Liver Cirrhosis and hepatocellular carcinoma Induced by Viral Hepatitis. , 2022, Virus research.

[4]  H. Abdelhady,et al.  MicroRNA-539-5p-Loaded PLGA Nanoparticles Grafted with iRGD as a Targeting Treatment for Choroidal Neovascularization , 2022, Pharmaceutics.

[5]  S. Shamsuddin,et al.  Drug release study of the chitosan-based nanoparticles , 2021, Heliyon.

[6]  Jinjun Shi,et al.  Polymeric nanoparticles for RNA delivery , 2021, Reference Module in Materials Science and Materials Engineering.

[7]  Yongheng Chen,et al.  Nanomaterials for cancer therapy: current progress and perspectives , 2021, Journal of Hematology & Oncology.

[8]  A. Kramvis,et al.  Epidemiology and aetiology of hepatocellular carcinoma in Sub-Saharan Africa , 2021, Hepatoma Research.

[9]  A. Dennison,et al.  Targeted therapy for hepatocellular carcinoma , 2020, Signal Transduction and Targeted Therapy.

[10]  Xiaoxue Jiang,et al.  Long noncoding RNA MEG3 blocks telomerase activity in human liver cancer stem cells epigenetically , 2020, Stem cell research & therapy.

[11]  A. Lampis,et al.  MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside , 2020, Targeted Oncology.

[12]  C. Swanton,et al.  Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis , 2020, Nature Communications.

[13]  S. Mahmoud,et al.  MicroRNA-195 vector influence on the development of gradually induced hepatocellular carcinoma in murine model , 2020, Ultrastructural pathology.

[14]  Wing-Cheung Law,et al.  Biodegradable Polymers for Gene-Delivery Applications , 2020, International journal of nanomedicine.

[15]  Xiaozhou He,et al.  LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2. , 2019, Journal of biochemistry.

[16]  A. Iyer,et al.  Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems. , 2019, Drug discovery today.

[17]  M. Taheri,et al.  Maternally expressed gene 3 (MEG3): A tumor suppressor long non coding RNA. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[18]  Liang Xie,et al.  lncRNA MEG3 inhibits the growth of hepatocellular carcinoma cells by sponging miR-9-5p to upregulate SOX11 , 2019, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[19]  Yali Gao,et al.  Long non-coding RNA MEG3 inhibits cervical cancer cell growth by promoting degradation of P-STAT3 protein via ubiquitination , 2019, Cancer cell international.

[20]  M. Soliman,et al.  Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles , 2019, Journal of Pharmaceutical Investigation.

[21]  Qinghua Guo,et al.  LncRNA2Target v2.0: a comprehensive database for target genes of lncRNAs in human and mouse , 2018, Nucleic Acids Res..

[22]  M. Bandehpour,et al.  In-vitro Transcribed mRNA Delivery Using PLGA/PEI Nanoparticles into Human Monocyte-derived Dendritic Cells , 2019, Iranian journal of pharmaceutical research : IJPR.

[23]  Yingying Zhang,et al.  LncRNA meg3 suppresses hepatocellular carcinoma in vitro and vivo studies. , 2019, American journal of translational research.

[24]  Jing Li,et al.  CRlncRNA: a manually curated database of cancer-related long non-coding RNAs with experimental proof of functions on clinicopathological and molecular features , 2018, BMC Medical Genomics.

[25]  Yeong-Su Jang,et al.  PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer , 2018, Scientific Reports.

[26]  Chong Du,et al.  Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer. , 2018, Oncology reports.

[27]  Zeping Han,et al.  Overexpression of Long Non‐Coding RNA MEG3 Inhibits Proliferation of Hepatocellular Carcinoma Huh7 Cells via Negative Modulation of miRNA‐664 , 2017, Journal of cellular biochemistry.

[28]  X. Wang,et al.  lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. , 2017, European review for medical and pharmacological sciences.

[29]  Jia Wen Liang,et al.  Aberrant Methylation-Mediated Silencing of lncRNA MEG3 Functions as a ceRNA in Esophageal Cancer , 2017, Molecular Cancer Research.

[30]  Longhua Chen,et al.  A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1 , 2017, Journal of Hematology & Oncology.

[31]  Dae Won Kim,et al.  Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. , 2017, Journal of gastrointestinal oncology.

[32]  P. Oliveira,et al.  Animal models as a tool in hepatocellular carcinoma research: A Review , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[33]  S. Tsao,et al.  Downregulation of long non‐coding RNA MEG3 in nasopharyngeal carcinoma , 2017, Molecular carcinogenesis.

[34]  Mathieu Laversanne,et al.  International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007 , 2016, International journal of cancer.

[35]  Lin Sun,et al.  Downregulated long non-coding RNA MEG3 in breast cancer regulates proliferation, migration and invasion by depending on p53's transcriptional activity. , 2016, Biochemical and biophysical research communications.

[36]  E. Mohit,et al.  Peptide/protein vaccine delivery system based on PLGA particles , 2016, Human vaccines & immunotherapeutics.

[37]  Beicheng Sun,et al.  The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma , 2016, Molecular carcinogenesis.

[38]  Jun Zhang,et al.  Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21 , 2016, Cancer biology & therapy.

[39]  Jinpeng Li,et al.  The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma , 2016, Tumor Biology.

[40]  Lisheng Wang,et al.  SENP1 regulates hepatocyte growth factor-induced migration and epithelial-mesenchymal transition of hepatocellular carcinoma , 2016, Tumor Biology.

[41]  Guosong Jiang,et al.  Long Non-Coding RNA MEG3 Inhibits Cell Proliferation and Induces Apoptosis in Prostate Cancer , 2015, Cellular Physiology and Biochemistry.

[42]  Juanjuan Zhu,et al.  Long Noncoding RNA MEG3 Interacts with p53 Protein and Regulates Partial p53 Target Genes in Hepatoma Cells , 2015, PloS one.

[43]  F. Wang,et al.  Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression , 2015, Journal of experimental & clinical cancer research : CR.

[44]  P. Mcneil,et al.  Effects of metal nanoparticles on the lateral line system and behaviour in early life stages of zebrafish (Danio rerio). , 2014, Aquatic toxicology.

[45]  Yutaka Ikeda,et al.  Impacts of PEGylation on the gene and oligonucleotide delivery system , 2014 .

[46]  Seung-Hoon Lee,et al.  Roles of Long Non-Coding RNAs on Tumorigenesis and Glioma Development , 2014, Brain tumor research and treatment.

[47]  M. Gorospe,et al.  Long Noncoding RNA MALAT1 Controls Cell Cycle Progression by Regulating the Expression of Oncogenic Transcription Factor B-MYB , 2013, PLoS genetics.

[48]  H. Tajmir-Riahi,et al.  Effect of PEG and mPEG-anthracene on tRNA aggregation and particle formation. , 2012, Biomacromolecules.

[49]  C. Croce,et al.  microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer , 2011, Oncogene.

[50]  A. Chow.  Cell Cycle Control by Oncogenes and Tumor Suppressors: Driving the Transformation of Normal Cells into Cancerous Cells , 2010 .

[51]  M. Grinstaff,et al.  Therapeutic and diagnostic applications of dendrimers for cancer treatment. , 2008, Advanced drug delivery reviews.

[52]  R. Drury.  Theory and Practice of Histological Techniques , 1983 .

[53]  Audrey M. Glauert,et al.  Fixation, dehydration and embedding of biological specimens , 1975 .